CRISPR Therapeutics AGCRSP

CRISPR Therapeutics AG (CRSP) reported a net loss of $122.9M in Q1 2026 despite holding $423.3M in cash, raising questions about the sustainability of its cash burn rate. Revenue from contracts with customers totaled just $1.5M, a figure dwarfed by its $68.6M R&D expenses and $130.2M operating loss. The company’s collaboration with Vertex Pharmaceuticals, which includes potential milestones of $410M, remains a critical lifeline, though deferred revenue from the partnership has stagnated at $12.3M since earlier reporting periods.

CRSP’s core business revolves around developing CRISPR/Cas9 gene-editing therapies, including CASGEVY™, which is approved in some jurisdictions for sickle cell disease and beta thalassemia. However, the company’s pipeline remains heavily weighted toward pre-commercial stages, with in vivo therapies targeting ANGPTL3, Lp(a), and other diseases still in clinical research. The firm’s cash reserves, while substantial, are being eroded by consistent operating losses, with net cash used in operations reaching $108.9M in Q1.

The company’s financials highlight a stark contrast between its scientific ambitions and commercial reality. With a diluted EPS of -$1.28 and 96.1M shares outstanding, CRSP’s equity story hinges on milestone achievements and regulatory approvals rather than near-term profitability. Its $2.73B in assets and $1.81B in stockholders’ equity provide a buffer, but the lack of material revenue growth since 2023 raises concerns about execution and market readiness.

CRSP’s chart shows a stock that has traded between $50 and $120 over the past year, reflecting speculative optimism around gene therapy despite the lack of commercial traction. However, the company’s liquidity profile remains robust, with no significant short-term liabilities threatening its operations. The key overhang is dilution risk: CRSP issued 96.1M diluted shares as of Q1, and continued cash burn may pressure management to raise capital through equity sales.

Investors await updates on CRSP’s in vivo programs, particularly the LNP-delivered therapies for cardiovascular targets. Regulatory progress for CASGEVY™ in additional markets and Vertex milestone payments remain near-term catalysts. However, the absence of revenue growth and the high burn rate mean the stock will likely remain volatile until the company demonstrates its ability to convert scientific promise into sustainable commercial success.